trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim
Antiviral drugs remain effective when started after a shingles outbreak
the verdict
REFUTED
the evidence says no
refutedsupported
the weight of evidence
0 sources for · 4 against

Evidence clearly refutes the claim that antiviral drugs remain effective when started after a shingles outbreak; clinical guidelines consistently emphasize that antivirals must be initiated within 72 hours of symptom onset to effectively reduce complications and pain.

Evidence against · 4
2024 · cited by 27
The study highlights that early initiation of antivirals, specifically within 72 hours of onset, is necessary to reduce severity, duration, and pain.
See more details
The analysis

The retrieved literature uniformly emphasizes that antiviral therapy for shingles (herpes zoster) must be initiated early—typically within 72 hours of rash onset—to be effective in reducing acute pain, lesion severity, and the risk of post-herpetic neuralgia or other complications. Studies that track treatment delays (such as papers [2], [8], and [10]) explicitly identify starting treatment after this window as a risk factor for poor outcomes, directly refuting the claim that they remain effective when started late.

More against · 3
2022 · cited by 11
The systematic review notes that starting treatment more than 72 hours after onset is associated with poor vision recovery in orbital apex syndrome.
2025 · cited by 1
The evaluation confirms that early antiviral therapy within the 72-hour window is associated with a lower incidence of postherpetic neuralgia.
2026 · cited by 0
The retrospective cohort analysis identifies an antiviral initiation delay of 3 days or more as a significant risk factor for postherpetic neuralgia.
The paper trail · every fact has a biography
first checked04 Aug 2026
judged → REFUTED · 904 Aug 2026
This receipt carries no identity, shared or not. Sharing publishes your connection to it, not your data.
Check your own claim
Challenge the receipt
trust me, bro: win the argument, pass the class, survive peer review.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt